Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma

Trial Profile

Phase I/Randomized Phase II Double Blind Study of Either Dasatinib or Placebo Combined With Bevacizumab in Recurrent Glioblastoma

Completed
Phase of Trial: Phase I/II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Dasatinib (Primary) ; Bevacizumab
  • Indications Astrocytoma; Glioblastoma; Oligodendroglioma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 31 Jul 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Nov 2015 as reported by ClinicalTrials.gov.
    • 02 Jun 2015 Primary endpoint Proportion of patients alive and progression-free has not been met as per results presented at the 51st Annual Meeting of the American Society of Clinical Oncology..
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed as per the results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top